Publicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (15)

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

  2. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2014

  1. Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors

    Critical Reviews in Oncology/Hematology, Vol. 89, Núm. 1, pp. 62-72

2013

  1. Finding the right dose of fulvestrant in breast cancer

    Cancer Treatment Reviews, Vol. 39, Núm. 2, pp. 136-141

  2. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Current perspectives of treatment of ductal carcinoma in situ

    Cancer Treatment Reviews, Vol. 36, Núm. 7, pp. 507-517

  3. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

  4. Supportive care for patients with early breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 1, pp. 32-42

2008

  1. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer

    Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709

  2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2007

  1. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials

    Cancer Treatment Reviews, Vol. 33, Núm. 5, pp. 474-483

  2. The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials

    Clinical Breast Cancer, Vol. 7, Núm. 10, pp. 764-774